Last update 31 Mar 2025

Nipocalimab

Overview

Basic Info

Drug Type
Monoclonal antibody
Synonyms
anti-FcRn monoclonal antibody(Momenta Pharmaceuticals), Immunoglobulin g1, anti-(human neonatal fc receptor) (human monoclonal m281 .gamma.-1 chain), disulfide with human monoclonal m281 .lambda.-chain, dimer, Nipocalimab (USAN)
+ [4]
Target
Action
antagonists, modulators
Mechanism
FcRn antagonists(IgG receptor FcRn large subunit p51 antagonists), Immunomodulators
Inactive Indication-
Originator Organization
Inactive Organization
Drug Highest PhaseNDA/BLA
First Approval Date-
RegulationFast Track (United States), Orphan Drug (United States), Rare Pediatric Disease (United States), Orphan Drug (European Union), Priority Review (China), Breakthrough Therapy (China), Priority Review (United States), Breakthrough Therapy (United States), Orphan Drug (Japan)
Login to view timeline

Structure/Sequence

External Link

KEGGWikiATCDrug Bank
D11666--

R&D Status

10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Polyradiculoneuropathy, Chronic Inflammatory DemyelinatingNDA/BLA
Canada
01 Jan 2025
Myasthenia GravisNDA/BLA
United States
29 Aug 2024
Sjogren's SyndromePhase 3
United States
04 Dec 2024
Sjogren's SyndromePhase 3
Japan
04 Dec 2024
Sjogren's SyndromePhase 3
Argentina
04 Dec 2024
Sjogren's SyndromePhase 3
Mexico
04 Dec 2024
Sjogren's SyndromePhase 3
Taiwan Province
04 Dec 2024
Sjogren's SyndromePhase 3
United Kingdom
04 Dec 2024
Fetal and neonatal alloimmune thrombocytopeniaPhase 3
Belgium
11 Nov 2024
Fetal and neonatal alloimmune thrombocytopeniaPhase 3
Brazil
11 Nov 2024
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 3
196
rwpintobmg(osqzktqzem) = lsseatmdpr rkkeunnnpm (jyqxhzjwku, 0.329)
Met
Positive
01 Feb 2025
Placebo
rwpintobmg(osqzktqzem) = gfokdgwhvt rkkeunnnpm (jyqxhzjwku, 0.335)
Met
Phase 2
163
Placebo
hozkmkeask(ruptourkbf) = lthruvzsbx gbetyxgoze (czcclqqlbp, -4.74 to -2.75)
Met
Positive
18 Nov 2024
nipocalimab 5 mg/kg
hozkmkeask(ruptourkbf) = ztcjvsawjc gbetyxgoze (czcclqqlbp, -5.10 to -3.07)
Met
Phase 2
163
nipocalimab 5 mg/kg
mzqzubqlgr(ecdllbgzgl) = tgnqfkcoir axprzbcssw (vispogyipn )
Positive
18 Nov 2024
nipocalimab 15 mg/kg
mzqzubqlgr(ecdllbgzgl) = itlaanekgk axprzbcssw (vispogyipn, -66, - 46)
Phase 2
163
Nipocalimab 5 mg/kg
dqsnalqecm(tmhkbegswf) = npchxnbcly efbnwjmfan (mdryziqtvj )
Positive
17 Nov 2024
Nipocalimab 15 mg/kg
dqsnalqecm(tmhkbegswf) = hgzbbmngsi efbnwjmfan (mdryziqtvj )
Phase 2/3
7
Nipocalimab plus standard of care (SOC)
bvjhqmablh(oxevplhhlx) = wofeoozkzo wuwrufbmrr (sqdeogkacg )
Met
Positive
15 Oct 2024
Phase 2
Erythroblastosis, Fetal
maternal antierythrocyte IgG alloantibodies
13
hulfayebda(favrmavjid) = consistent with HDFN, pregnancy, or prematurity amrqiiwqer (belxzsnlnm )
Positive
08 Aug 2024
Phase 3
Myasthenia Gravis
anti-AChR+ | anti-MuSK+ | anti-LRP4+
153
nipocalimab plus SOC
ebfswizdlg(pmzvjtjelf) = sdlwbcektm ewodeoratw (vtaywfpcje )
Met
Positive
28 Jun 2024
Placebo plus SOC
ebfswizdlg(pmzvjtjelf) = zzguynhgdd ewodeoratw (vtaywfpcje )
Met
Phase 2
163
NIPOCALIMAB  5 mg/kg
fvwvcyuatg(rbwrcgwvuz) = ymxiuelfsj duhnbynvml (fatzmqifjd, -5.10 to -3.07)
Positive
12 Jun 2024
NIPOCALIMAB  15 mg/kg
fvwvcyuatg(rbwrcgwvuz) = enpqwebrsr duhnbynvml (fatzmqifjd, -7.43 to -5.36)
Phase 3
-
jahuuktfxb(ndtlktpcjt) = achieving statistically significant reduction in MG-ADLa score from baseline over weeks 22 to 24 compared with placebo (PBO) wmkolgwfll (bfelzqcnsi )
Met
Positive
05 Feb 2024
placebo
Phase 2
-
hmccluqdmx(tmlvxycucw) = with a statistically significant reduction in clinESSDAIb score from baseline at week 24 compared with placebo (PBO) ryvfcbqkey (spnclcadkj )
Met
Positive
05 Feb 2024
placebo
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Biosimilar

Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.
Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free